Synthetic Biologics Inc (NYSEAMERICAN:SYN) Short Interest Down 32.2% in November

Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw a significant decline in short interest in the month of November. As of November 29th, there was short interest totalling 51,200 shares, a decline of 32.2% from the November 14th total of 75,500 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 83,600 shares, the short-interest ratio is currently 0.6 days.

NYSEAMERICAN SYN traded up $0.01 on Wednesday, reaching $0.41. 81,100 shares of the company’s stock traded hands, compared to its average volume of 165,214. Synthetic Biologics has a fifty-two week low of $0.37 and a fifty-two week high of $0.85.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.31) earnings per share for the quarter.

An institutional investor recently bought a new position in Synthetic Biologics stock. Wedbush Securities Inc. purchased a new stake in Synthetic Biologics Inc (NYSEAMERICAN:SYN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 97,957 shares of the company’s stock, valued at approximately $54,000. Wedbush Securities Inc. owned approximately 0.58% of Synthetic Biologics as of its most recent SEC filing.

About Synthetic Biologics

Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.

Recommended Story: How to find the components of the quick ratio

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.